From 2e38ea164d32a0cc47ac42dfb24a05de1a380feb Mon Sep 17 00:00:00 2001
From: Isabell Alexandra Guckes <isabell.guckes@uni-bielefeld.de>
Date: Wed, 25 Sep 2024 18:34:58 +0000
Subject: [PATCH] Update file drug-data.tsx
---
src/data/drug-data.tsx | 4 ++--
1 file changed, 2 insertions(+), 2 deletions(-)
diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 3be90a46..203f9fa6 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -4,7 +4,7 @@ export interface DrugDatensatz {
picture: string;
introduction: string;
examples: Array<example>;
-
+
}
@@ -37,7 +37,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
examples: [
{
title: "Trikafta", //quelle 4
- text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation à 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
+ text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation = 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
},
{
title: "Symdeko", //quelle 1
--
GitLab